Evidence map›Paper›PMID 25368322›Full record

ArticleThe Journal of biological chemistry2015

Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation.

Daniel Horbelt, Jan H Boergermann, Apirat Chaikuad, Ivan Alfano, Eleanor Williams, Ilya Lukonin, Tobias Timmel, Alex N Bullock, Petra Knaus

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Structural biology of the TGFβ family.Experimental biology and medicine (Maywood, N.J.) · 2019
    Review
  16. Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP Mesenchymal Progenitors for Osteogenesis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019
    Article
  17. Article
  18. Pharmacologic Strategies for Assaying BMP Signaling Function.Methods in molecular biology (Clifton, N.J.) · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Daniel HorbeltFrom the Institute for Chemistry-Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.
Jan H BoergermannFrom the Institute for Chemistry-Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.
Apirat Chaikuadthe Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, United Kingdom, and.
Ivan Alfanothe Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, United Kingdom, and.
Eleanor Williamsthe Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, United Kingdom, and.
Ilya LukoninFrom the Institute for Chemistry-Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.
Tobias Timmelthe Muscle Research Unit, Experimental and Clinical Research Center, 13125 Berlin, Germany.
Alex N Bullockthe Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, United Kingdom, and.
Petra KnausFrom the Institute for Chemistry-Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany, knaus@chemie.fu-berlin.de.
Freie Universität Berlin · DEUniversity of Oxford · GBGenomics (United Kingdom) · GB

Funding

Wellcome Trust 092809Wellcome Trust 092809/Z/10/Z
6 · The paper itself

Abstract

GDF8, or myostatin, is a member of the TGF-β superfamily of secreted polypeptide growth factors. GDF8 is a potent negative regulator of myogenesis both in vivo and in vitro. We found that GDF8 signaling was inhibited by the small molecule ATP competitive inhibitors dorsomorphin and LDN-193189. These compounds were previously shown to be potent inhibitors of BMP signaling by binding to the BMP type I receptors ALK1/2/3/6. We present the crystal structure of the type II receptor ActRIIA with dorsomorphin and demonstrate that dorsomorphin or LDN-193189 target GDF8 induced Smad2/3 signaling and repression of myogenic transcription factors. As a result, both inhibitors rescued myogenesis in myoblasts treated with GDF8. As revealed by quantitative live cell microscopy, treatment with dorsomorphin or LDN-193189 promoted the contractile activity of myotubular networks in vitro. We therefore suggest these inhibitors as suitable tools to promote functional myogenesis.

Indexed as

Cell DifferentiationSignal TransductionActivin Receptors, Type IIAmino Acid SequenceAnimalsBinding SitesHumansMiceMolecular Sequence DataMyoblastsMyostatinProtein BindingPyrazolesPyrimidinesSf9 CellsSmad2 ProteinActivin Receptors, Type IIactivin receptor type II-AdorsomorphinLDN 193189MyostatinPyrazolesPyrimidinesSmad2 ProteinSmad3 ProteinTranscription FactorsBone Morphogenetic Protein (BMP)MyogenesisMyostatinSerine/Threonine Protein KinaseSmall Molecule

Identifiers

PMID25368322
PMCPMC4319009
OpenAlexW2073397316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.